Guidance ledger · Q4 FY26

Metropolis Healthcare Ltd METROPOLIS

4 revisions on record · 0 lowered · 3 raised — the strikethrough is what management used to say

gives specific guidance · held across quarters

Holding view → · latest concall · The pulse

↑ raised Revenue growth multi-year framework Q4 FY25 → Q4 FY26

~~FY26 organic 12% to 13%~~ → FY27-FY29 CAGR 14% to 15%

“Over the next 3 years, the vision is to grow at a CAGR of 14% to 15% in revenue”

↑ raised Group EBITDA margin multi-year target Q2 FY26 → Q4 FY26

~~70-100 bps annual progression~~ → Sustainable 27% to 28% over next 3 years

“the goal of achieving a sustainable group EBITDA margin of 27% to 28% over the next 3 years”

↑ raised Next-fiscal EBITDA margin improvement Q3 FY26 → Q4 FY26

~~12% to 13% organic growth (FY26 guide)~~ → 125 to 150 bps EBITDA improvement (FY27 guide)

“we'll definitely be looking at about 125 to 150 bps improvement in the coming year”

→ narrowed Core Diagnostics EBITDA exit (Q4FY26) Q1 FY26 → Q4 FY26

~~high-single-digit EBITDA exit promise (4-quarter horizon)~~ → high-single-digit Q4FY26 EBITDA delivered + 20%-plus 3-year

“we have committed that within 4 quarters of doing the acquisition, we would move from a negative 2% EBITDA to a high -single-digit EBITDA in Q4. We have completed this mission”

Method. Revisions come from management's own stated numbers, compared quarter over quarter across the covered concalls; each carries the verbatim quote. “No revisions” can also mean guidance too vague to pin down — see the posture chip above. Not investment advice.